"Reactive" or activated stroma characterizes many malignancies including breast cancers. Recently, we isolated a reactive mouse mammary gland stromal cell line called BJ3Z. These cells express α-smooth muscle actin and stromal cell-derived factor 1 (SDF-1) and are tumorigenic when injected into mice. Here we show that, in vivo, BJ3Z cells influence the angiogenesis and proliferation of xenografted estrogen receptor (ER)-positive MCF-7 human breast cancer cell-derived solid tumors. The growth-promoting effects of BJ3Z cells are equivalent to those of estradiol (E 2 ). BJ3Z cells also increase the proliferation of normal mouse mammary luminal cells adjacent to tumors. In vitro, BJ3Z cells reorganize and increase the proliferation of cocultured malignant MCF-7 and normal human breast MCF10A cells grown as organoids in three-dimensional culture. The effects of BJ3Z cells on MCF-7 cells are equivalent to those of E 2 . In contrast, BJ3Z cells do not alter the growth of highly aggressive ER-negative MDA-MB-231 human breast cancer cells. We show that BJ3Z cells secrete vascular endothelial growth factor (VEGF). The growth of MCF-7 organoids induced by BJ3Z can be inhibited by antagonists of VEGF and SDF-1. Conversely, recombinant VEGF stimulates the proliferation of MCF-7, but not MDA-MB-231, organoids. We conclude that, in addition to angiogenesis, VEGF released by activated stroma increases the growth of ER-positive malignant epithelial cells and of adjacent normal epithelium. Because activated stroma can substitute for E 2 and fosters hormone-independent growth of ER-positive tumors, we suggest that breast cancers exhibiting intrinsic hormone resistance may respond to antiangiogenic therapies.
Introduction
For several decades, cancer research has focused on the genetics and tumor biology of adenocarcinomas. In the breast, such cancers originate from luminal epithelial cells that line the alveoli and ducts (1) . Recent studies have shown the importance of stromal influences on epithelial cells in a wide variety of normal biological processes, including embryonic development and wound healing, and in malignancies including tumorigenesis and tumor growth (2) (3) (4) (5) . "Reactive" or activated stroma or desmoplasia is a common feature of many malignancies (6) (7) (8) . Coinjection into mice of activated, carcinoma-associated fibroblasts (CAF) with Ras-mutant MCF-7 human breast cancer cells generates large tumors, associated with recruitment of bone marrow-derived angiogenic endothelial progenitor cells (9) . One mediator of this CAF effect is stromal derived factor 1 (SDF-1; CXCL12), which increases the proliferation of Ras-mutant MCF-7 cells by binding surface CXCR-4 receptors. CXCR-4 is expressed in a variety of breast cancer cells but is absent in normal mammary epithelial cells. SDF-1 is a chemoattractant that enhances the migratory behavior of cell lines (10) . Interestingly, overexpression of SDF-1 is observed in normal lymph nodes, lungs, liver, and bone marrow, the most common sites for breast cancer metastasis (10) , suggesting that SDF-1 also serves a homing function for migratory tumor cells.
Angiogenesis is the physiologic process by which new blood vessels are generated. Breast tumors and many other solid tumors require this fundamental step to grow beyond a few millimeters in diameter (11) . Vascular endothelial growth factor (VEGF) is a potent and selective endothelial mitogen able to induce a rapid and complete angiogenic response in normal and malignant tissues by generating new blood vessels. In addition to being secreted by a number of different cell types, VEGF is overexpressed not only by breast cancer cells but also by activated breast stromal cells, suggesting an active role for the latter in tumor growth and angiogenesis (12) . Interestingly, VEGF expression in breast cancer cells can stimulate CXCR-4, linking VEGF expression to the migratory potential of cells (13) and to SDF-1 signaling.
Most breast cancers are "luminal" and express estrogen receptors (ER) and/or progesterone receptors. The receptors identify patients whose tumors are likely to be hormone dependent or hormone responsive and are candidates for endocrine therapies that suppress the proliferative effects of estrogens by targeting either ER or estradiol (E 2 ) biosynthesis. However, despite the presence of the receptors, approximately half of luminal breast cancers exhibit intrinsic hormone resistance; tumors fail to respond or continue to expand at initial treatment. Such intrinsic resistance has been ascribed to a variety of factors including mutant ER, unbalanced ratios of ER coregulators, excessive growth factor signaling, and, in some cases, unspecified "host" factors.
Recently, we isolated and characterized an activated mouse mammary gland stromal cell line, called BJ3Z, that expresses α-smooth muscle actin (α-SMA), SDF-1, and other factors (14) . We now show that, in vivo, BJ3Z cells influence the angiogenesis and proliferation of xenografted ER + MCF-7 human breast cancer cell-derived solid tumors. The growthpromoting effects of BJ3Z cells are equivalent to those of E 2 . BJ3Z cells also increase the proliferation of normal mouse mammary luminal cells adjacent to tumors. In vitro, BJ3Z cells reorganize and increase the proliferation of cocultured malignant MCF-7 and normal breast MCF10A cells grown as organoids in three-dimensional (3D) culture. The effects of BJ3Z cells on MCF-7 cells are equivalent to those of E 2 . In contrast, BJ3Z cells do not alter the growth of highly aggressive ER − MDA-MB-231 breast cancer cells. The 3D culture models faithfully replicate in vivo conditions. BJ3Z cells secrete VEGF and express SDF-1. Analogous to BJ3Z cells, recombinant VEGF (rVEGF) stimulates the proliferation of MCF-7, but not MDA-MB-231, organoids. We conclude that activated stroma can increase the aggressiveness and tumorigenicity of malignant epithelial cells and adjacent normal epithelium. Additionally, activated stroma can substitute for E 2 to foster hormone-independent growth of luminal tumors.
Materials and Methods
Cell lines. MCF-7 and MDA-MB-231 human breast cancer cells and immortalized normal human breast epithelial MCF10A cells were obtained from the American Type Culture Collection or the University of Colorado Cancer Center Tissue Culture Core. All cell lines were authenticated by single tandem repeat analysis at the Sequencing Core. Transformed mouse mammary stromal BJ3Z cells were developed in our laboratory (14) . Cells were passaged in MEM (Invitrogen) containing 5% fetal bovine serum (HyClone), except for MCF10A, which were grown in mammary epithelial growth medium (Lonza). BJ3Z cells were tagged with red tandem-dimer Tomato (RedTomato; ref. 15) as described (16) .
Xenografts and tumor isolation. All animal procedures were done under a protocol approved by the CU Institutional Animal Care and Use Committee. ZsGreen-tagged MCF-7 cells (10 6 ; ref. 16) or RedTomato-tagged BJ3Z cells (10 6 ) or both (2 × 10 6 cells) were injected into mammary fat pads of ovariectomized (ovx) athymic nu/nu mice. 17β-Estradiol (E 2 ) or cellulose-releasing silastic pellets were implanted s.c. (16) . Mice were weighed and tumor areas measured weekly with digital calipers for 10 to 12 wk. Two hours before necropsy, mice were injected i.p. with 100 mg/kg bromodeoxyuridine (BrdUrd) in PBS. At necropsy, fluorescent tumors and metastases were visualized using Ilumatools 9900 (Lightools Research) and photographed with an Olympus C-5050 digital camera coupled to an Olympus SZ-61 dissecting microscope. Dissected tissues and tumors were fixed overnight in 4% paraformaldehyde, embedded in paraffin blocks, and sectioned (5 μm) for pathologic review by H&E staining and for immunohistochemistry and other analyses.
Immunohistochemistries. For CD34, the primary antibody (1:50 dilution; Abcam) was applied for 1 h, followed by Alexa 488 goat anti-rat secondary (1:300; Invitrogen). The other primary antibodies were vimentin (sc-7557, Santa Cruz Biotechnology), fibroblast activation protein (FAP; ab-53066, Abcam), α-SMA (1184-S, Epitomics), SDF-1 (mAb-350, R&D Systems), and antimouse panCK (BioLegend). The secondary antibodies were Alexa 488 goat anti-mouse (1:500), Alexa 488 donkey anti-goat (1:500), and Alexa 555 goat anti-rabbit (1:400; Invitrogen). Slides were imaged using a Nikon Eclipse E600 fluorescent microscope (Nikon Corporation) coupled to an RGB-MS-C MicroColor camera (CRI, Inc.). Quantification of at least five fields and two tumors per condition used Image Pro Plus 4.5 software (Media Cybernetics).
CK18/BrdUrd or E-cadherin proliferation assay. BrdUrd incorporation was calculated by double staining for human CK18 (rabbit polyclonal; Calbiochem) and BrdUrd (mouse monoclonal; Becton Dickinson). Red Alexa 555 goat antirabbit and green Alexa 488 goat anti-mouse antibodies (Invitrogen) allow their simultaneous detection (CK18/BrdUrd assay) after counterstaining the nuclei with blue fluorescent 4′,6-diamidino-2-phenylindole (DAPI). Proliferation rates of human cells were calculated by the ratio of BrdUrd + nuclei (green) to DAPI + nuclei (blue) in CK18 + cells (red) using Image Pro in 5 to 10 fields from at least two tumors or four organoids per condition. Normal luminal epithelial cells adjacent to tumors were double stained for E-cadherin (Abcam) and BrdUrd and quantified by counting BrdUrd + versus total nuclei in E-cadherin + structures. 3D organoids. Three-dimensional cultures were performed as described (17) with minor modifications. Briefly, eight-well slides were coated with 50 μL of growth factorreduced Matrigel (BD Biosciences). Cells were trypsinized and resuspended in MEM containing 5% twice dextran-coated charcoal (DCC)-stripped serum (DCC/MEM). Breast cancer cells (10,000) and/or BJ3Z cells (50,000) were layered on Matrigel and cultures were maintained for ∼7 d, adding fresh medium every 2 or 3 d. For MCF10A, 10,000 cells were resuspended in 2% donor horse serum in mammary epithelial growth medium. To calculate proliferation indices, 7-d-old organoids were incubated with 0.25 mg/mL BrdUrd in 5% DCC/ MEM for 1 h. Immunohistochemistry for MCF-7 cells used the CK18/BrdUrd assay; for MCF10A and MDA-MB-231 cells, CK14 (rabbit polyclonal; Thermo) and CD44 (rabbit monoclonal; Epitomics) antibodies, respectively, were substituted for CK18. A minimum of four fields in four sections were quantified at least in triplicates.
Hormone treatments in vitro. Organoids were cultured in 5% DCC/MEM for 5 d and then switched to 5% DCC in phenol red-free MEM containing ethanol (1:1,000, v/v) or 10 nmol/L E 2 .
Antibody array. BJ3Z organoids were cultured for 2 or 4 d and then switched to serum-free MEM for 48 h. Controls consisted of a Matrigel-coated chamber without cells. Supernatants from control or BJ3Z cells were collected, centrifuged, and hybridized to a TranSignal mouse angiogenesis antibody array (Panomics) as instructed.
Anti-VEGF and SDF-1 blockade. MCF-7/BJ3Z cocultures were incubated for 7 d with antimouse VEGF monoclonal antibody (VEGF mAb; R&D Systems) or Avastin (bevacizumab; Genentech, Inc.) at 0.1 μg/mL or the CXCR-4 antagonist AMD 3100 (Sigma) at 5 μg/mL, refreshed every 48 h. On day 7, the proliferation rate of organoids was calculated using the CK18/BrdUrd assay.
Recombinant human VEGF. Cells were treated for 7 d with 0.1, 1, or 10 ng/mL human or mouse rVEGF (R&D Systems) and refreshed every 2 d; proliferation rates were calculated.
Phosphorylated extracellular signal-regulated kinase. Monocultured cells were treated with 10 ng/mL rVEGF or vehicle (0.1% bovine serum albumin in PBS) for 0, 10, or 30 min and 2 or 6 h. Phosphorylated extracellular signalregulated kinase (p-ERK) was assayed by immunohistochemistry (rabbit polyclonal; Neuromics).
Statistical analyses. Data were analyzed with GraphPad software using either Student's t test or ANOVA followed by a Tukey's posttest; P ≤ 0.05 was considered significant.
Results
BJ3Z cells are tumorigenic and influence the growth and angiogenesis of MCF-7 tumors. Previously, we showed that BJ3Z stromal cells are tumorigenic when injected into mammary fat pads of nude mice (14) . To track their effects in vivo, BJ3Z cells were tagged with RedTomato fluor. Red BJ3Z cells, either alone or mixed with ZsGreen-tagged MCF-7 cells (16), were grown 10 weeks in the mammary glands of ovx nude mice with control (n = 5) or E 2 (n = 10) pellets (Fig. 1A) Because BJ3Z tumors exhibited increased surface vascularity, the endothelial cell marker CD34 was used to quantify intratumoral angiogenesis (Fig. 1C) . In vitro, neither MCF-7 nor BJ3Z cells express CD34. In the absence of E 2 , angiogenesis in pure BJ3Z tumors and mixed BJ3Z/MCF-7 tumors is significantly higher (ANOVA, P = 0.0013) than in pure MCF-7 tumors. The same pattern is observed in the presence of E 2 . Because in MCF-7 cells alone, E 2 seemed to have no effect on intratumoral blood vessel density, we conclude that E 2 does not influence tumoral vascularization; rather, BJ3Z cells stimulate recruitment of CD34 + cells into tumors.
BJ3Z cells cause an increase in MCF-7 cell proliferation in tumors and adjacent normal epithelium. Because mixed BJ3Z/MCF-7 tumors were enlarged, we examined the proliferative activity of the MCF-7 subpopulation by quantifying BrdUrd incorporation (green) into CK18 + (red) malignant human epithelial cells ( Fig. 2A and B) . Figure 2A shows that in pure MCF-7 tumors, E 2 increases proliferation rate as assessed by the increased number of CK18/BrdUrd doublepositive cells. The proliferative effects of E 2 in ER + breast cancers are well known (16) . However, Fig. 2A shows that MCF-7 proliferation is increased equally by the presence of BJ3Z cells, even in the absence of E 2 . Quantitation of the data (Fig. 2B) shows that BJ3Z cells and E 2 independently increase the proliferation rate of MCF-7 cells in a statistically significant but nonadditive manner.
The proliferative stimulation by BJ3Z cells of MCF-7 cells in the absence of E 2 prompted us to ask whether proliferation of adjacent normal mouse epithelium was similarly affected. Figure 2C shows H&E-stained sections and matched serial sections stained for mouse E-cadherin (red) and BrdUrd (green) from cellulose-treated mice bearing BJ3Z tumors, MCF-7 tumors, or mixed MCF-7/BJ3Z tumors. Quantitation is shown in Fig. 2D . The presence of BJ3Z cells alone or in mixed tumors markedly increased the proliferation rate of adjacent normal mouse mammary epithelial cells. Clearly, in Figure 2 . BJ3Z cells enhance the proliferation of MCF-7 cells and of adjacent normal mammary tissue in the absence of E 2 . A, ovx nude mice were implanted in mammary glands with MCF-7 cells alone or MCF-7/BJ3Z cell mixtures. Mice were supplemented with cellulose (C) or E 2 -releasing pellets. Tumors were grown for 10 wk. Slides were stained by immunohistochemistry against CK18 (red) and BrdUrd (green). Bar, 50 μm. B, BrdUrd incorporation was quantified; * and #, P < 0.05, ANOVA followed by Tukey's posttest. C, tumors were grown as above in mice receiving BJ3Z cells only, MCF-7 cells only, or BJ3Z/MCF-7 cell mixtures, all in the absence of E 2 . Slides from tumors were stained with H&E (left). Serial sections were stained by immunohistochemistry (right) for normal E-cadherin-positive cells (red) and BrdUrd (green nuclei). D, quantitation of BrdUrd incorporation; *, P < 0.05. the absence of E 2 , transformed BJ3Z stromal cells are capable of increasing the proliferation of normal and malignant mammary epithelia in their vicinity.
Modeling the influence of BJ3Z cells in 3D cultures. BJ3Z stromal cells influence epithelial tumors in vivo by increasing growth and vascularization. To define the mechanisms involved, we sought an in vitro model from which cell-secreted factors could be collected and analyzed. Recent studies have shown that cells grown in vitro in a 3D matrix recapitulate essential features of solid tumors including gene expression patterns and protein function (18, 19) . Figure 3 shows the morphology and quantitation of BrdUrd incorporation of 3D organoids formed by ER + MCF-7 cells, normal ER − human epithelial MCF10A cells, and highly aggressive ER − MDA-MB-231 human breast cancer cells, cultured alone or together with BJ3Z cells. MCF-7 cells in 3D monoculture form dense disorganized clusters or "masses" of variable size (Fig. 3A,  top) , characterized by irregular colonies with filled centers (18) . When cocultured with BJ3Z cells (Fig. 3A, bottom) , MCF-7 cells form an organized layer that encapsulates the BJ3Z cells. In these mixed MCF-7/BJ3Z structures, proliferation of the CK18 + (red)/BrdUrd + (green) MCF-7 cell subpopulation is significantly increased (Fig. 3A, right) , a pattern similar to that observed in tumors (Fig. 2B) . Normal mammary fibroblasts do not influence MCF-7 proliferation under these conditions (data not shown). Treatment of pure MCF-7 colonies with E 2 caused the expected increase in proliferation, akin to the levels induced by BJ3Z cells and showing E 2 responsiveness of MCF-7 cells in 3D conditions. The proliferative effects of BJ3Z and E 2 were similar but not additive, again reflecting the solid tumors.
Because in tumors, the presence of BJ3Z cells increased the proliferation of adjacent normal mammary epithelial cells (Fig. 2C and D) , we evaluated this in 3D organoids using normal human mammary epithelial MCF10A cells. In monoculture, MCF10A cells form rounded hollow structures that proliferate sluggishly (Fig. 3B, top) , as described (17), analogous to normal mammary epithelial cells in situ (20) . In coculture, MCF10A cells organize into lobular structures surrounding BJ3Z cells (Fig. 3B ) with significantly increased proliferation (Fig. 3B, right) . These in vitro effects of BJ3Z cells on MCF10A cells mimic their effects on normal mammary epithelial cells in vivo and further validate the 3D model.
In monoculture, the highly metastatic ER − MDA-MB-231 breast cancer cell line forms "snowflake" or "stellate" colonies with projections (ref. 18 ; Fig. 3C ) that bridge multiple cell colonies and can organize into a continuous network. This is considered characteristic of an invasive phenotype. causes no change in their proliferation (Fig. 3C) . In coculture, thin layers of MDA-MB-231 cells mold themselves around a dense core of quiescent BJ3Z cells. In sum, BJ3Z cells selectively influence a subset of epithelial cells characterized by low aggressiveness. Molecular markers of BJ3Z cells in tumors and organoids. To further characterize the properties of BJ3Z cells in tumors versus 3D organoids, we examined the protein expression of key molecular markers under both conditions (Fig. 4A) . Top images show the morphology of BJ3Z tumors and organoids stained with H&E. Whether grown as tumors or in 3D, BJ3Z cells express classic activated fibroblast markers: FAPα, SDF-1, α-SMA, and vimentin. BJ3Z cells do not express multiple epithelial cytokeratins (PanCK). Thus, BJ3Z cells are stromal cells with similar biological properties in 3D culture and tumors. We therefore used supernatants of cells grown in 3D to probe a mouse antibody array for BJ3Z-secreted factors that may explain their influence on epithelial cells (Fig. 4B) . BJ3Z grown in 3D secrete high levels of VEGF and tissue inhibitor of metalloproteinase-1 (TIMP-1; Fig. 4B, boxed) . Both factors are expressed by activated stroma (12, 21) , and we analyzed VEGF in greater detail.
BJ3Z cells enhance epithelial proliferation through VEGF and SDF-1. VEGF is secreted by BJ3Z cells in organoids, and SDF-1 is expressed in both BJ3Z tumors and organoids. Both factors increase proliferation of breast cancer cells (22, 23 ). An antimouse VEGF mAb, the humanized anti-VEGF mAb Avastin (bevacizumab), and AMD 3100, a blocker of the SDF-1 receptor CXCR-4, were tested for their effects on MCF-7 proliferation in BJ3Z cocultures (Fig. 5A ). In the presence of BJ3Z cells, VEGF mAb and AMD 3100 significantly decreased BrdUrd incorporation into MCF-7 cells, suggesting that VEGF and/or SDF-1 mediate BJ3Z-induced MCF-7 cell proliferation. Avastin had no significant effect (Fig. 5A ) because it is highly human specific (24) and does not target murine VEGF. On the other hand, human VEGF should be able to influence MCF-7 cells directly. Indeed, human rVEGF between 0.1 and 10.0 ng/mL significantly increased BrdUrd incorporation into monocultured MCF-7 cell organoids (Fig. 5B,  black columns) . Despite similar basal proliferation levels, rVEGF had no effect on BrdUrd incorporation into MDA-MB-231 cells (Fig. 5B, white columns) , perhaps explaining their unresponsiveness to BJ3Z cells. Similar results were obtained for both breast cancer cell lines using mouse rVEGF (not shown).
Among the three VEGF receptors, VEGFR-2 (KDR/Flk-1) is expressed by endothelial cells and is responsible for the proliferative activity of VEGF (25) . VEGFR-2 activation leads to Raf-1/MEK and p-ERK upregulation (26) . Because both MCF-7 and MDA-MB-231 cells express comparable levels of VEGFR-2 (27) and total ERK (28), we investigated their p-ERK expression in response to rVEGF (Fig. 5C ). Basal p-ERK levels were low in MCF-7 organoids, but rVEGF rapidly (10 minutes) augmented their levels. In contrast, p-ERK levels were constitutively high in MDA-MB-231, which were unchanged by rVEGF. MDA-MB-231 cells possessed both K-Ras and B-Raf mutations that trigger p-ERK overexpression (29, 30) , which may explain their unresponsiveness to VEGF and BJ3Z cells. A, MCF-7/ BJ3Z cocultures were incubated with a blocking antimouse VEGF mAb or Avastin (bevacizumab) or with the CXCR-4 blocker AMD 3100 for 7 d. On day 7, cells were processed as described and the proliferation rate was calculated using the CK18/BrdUrd proliferation assay; *, P < 0.05. B, BrdUrd incorporation in MCF-7 and MDA-MB-231 monocultures treated with rVEGF for 7 d; *, P < 0.05. C, seven-day-old MCF-7 or MDA-MB-231 organoids were treated for 10 min with vehicle (control) or rVEGF and then processed and stained by immunohistochemistry against p-ERK. Bar, 50 μm.
growth, metastatic potential, and possibly in determining the destination of metastatic cells and the outcome of therapies. Fibroblasts are the major stromal cell types, and in tumors, they acquire an "activated" phenotype characterized by increased proliferation and motility and heightened expression levels of α-SMA (31) and other factors. Under these conditions, fibroblasts are generally called carcinoma-associated fibroblasts (CAF). Here we report that activated malignant mouse stromal BJ3Z cells (14) , either alone or mixed with MCF-7 cells, generate highly vascularized solid tumors containing increased intratumoral CD34 + vascular endothelial cells, both indicative of enhanced angiogenesis. Such tumors may be highly aggressive and metastatic. Because neither BJ3Z cells nor MCF-7 cells express CD34, we hypothesize that upregulation of CD34-positive cells in tumors containing BJ3Z cells is due to recruitment of vascular endothelial cells in response to VEGF secretion. It is postulated that endothelial precursor cells originate in bone marrow and travel to the tumor mass via the circulation attracted there by VEGF (32, 33) . Endothelial precursors may also arise from nearby capillaries (33). Orimo and colleagues (9) showed that coinjection of human CAFs with Ras-mutant MCF-7 cells generated highly vascularized tumors. They proposed that the increased angiogenesis was caused by CAF expression of SDF-1 leading to recruitment of endothelial progenitor cells from bone marrow. Additionally, SDF-1 expression by CAFs increased proliferation of MCF-7 by direct activation of the SDF-1 receptor CXCR-4. Both the VEGF and the SDF-1 pathways are activated in our BJ3Z-containing tumor models (Fig. 5A) and could explain the angiogenesis we observe in mixed MCF-7 tumors (Fig. 2C and D) in the absence of E 2 supplementation or introduction of Ras mutations.
Activated stroma and normal epithelia. It is widely recognized that the stroma plays a key role in normal tissue development and homeostasis (34) . In fact, many years ago, normal stroma was shown to suppress the expression of the neoplastic phenotype (35, 36) . Conversely, malignant stroma actively influences breast carcinogenesis (37, 38) . Here we show that the presence of BJ3Z cells in tumors increases the proliferative activity of adjacent normal epithelium. Similarly, we show that coculture of BJ3Z cells with normal human breast epithelial MCF10A cells in organoids strongly increases the proliferation of the normal cells, suggesting an active role for malignant stroma in influencing the behavior of normal epithelium. Indeed, irradiated or N-nitrosourea-treated (both carcinogenic events) stroma transplanted into cleared mammary fat pads induces tumors in cotransplanted normal mammary epithelial cells (39, 40) . We speculate that in normal epithelium, malignant stroma influences tumorigenesis by increasing proliferation, raising the likelihood of mutagenesis. In the early stages of cancer, malignant stromal cells would increase the proliferation and inhibit the apoptosis of nearby carcinoma cells, stimulate angiogenesis, promote acquisition of de novo mutations, and foster aggressive behavior.
VEGF, SDF-1, and intrinsic hormone resistance. Threedimensional culture systems have become accepted alternatives to the use of animal models (41) . They have proved to be valuable tools to study the behavior of cells and the signaling pathways governing epithelial-stromal interactions in an environment that closely resembles the microenvironment of cells in tissues (42) (43) (44) . Here we show that BJ3Z cells express a similar pattern of molecular markers in tumors and 3D organoids; that coculturing BJ3Z cells in vitro or in solid tumors causes a similar increase in MCF-7 proliferation; that BJ3Z cells induce similar increases in proliferation of normal mammary cells in organoids and tumors; and that BJ3Z cells can substitute for the proliferative effects of E 2 in tumors and organoids. Our data point to a role of SDF-1 and VEGF for these effects. Previous studies have shown that VEGF regulates CXCR-4 levels, suggesting that the two factors act cooperatively in breast cancers (13) . Both factors have been previously associated with metastatic breast cancers: CXCR-4 activation is implicated in metastasis to the bone and lung (10) , and a recent study identified a VEGF gene "signature" composed of 13 related genes as a strong prognostic indicator in breast cancers (45) . We hypothesize that VEGF secretion by BJ3Z exerts a dual action in tumors: enhancing the recruitment of CD34-expressing cells, leading to endothelial cell proliferation and neovascularization, and directly activating breast cancer cell proliferation. The latter effect of VEGF has been previously observed in MCF-7 cells engineered to overexpress VEGF (22). In our studies, VEGF is supplied by stromal cells. Interestingly, unlike ER + MCF-7 cells, highly aggressive ER − MDA-MB-231 cells are insensitive to BJ3Z cells or to treatment with VEGF. A related study, also using organoids, showed that MDA-MB-231 cell proliferation, unlike that of ER + cell lines, is unaffected by the presence of human bone marrow stromal cells (46) . The authors postulated that ER − and/or triple-negative basal breast cancers, like those represented by MDA-MB-231, have acquired multiple K-Ras, B-Raf, and p53 mutations (30, 47) allowing E 2 -independent growth. This could explain the disappointing efficacy of long-term antiangiogenic or anti-VEGF directed therapies such as bevacizumab on overall survival of late-stage HER2-negative, triple-negative disease (48, 49) . Most clinical trials of antiangiogenic therapies focus on combinations with chemotherapeutic agents targeting recurrent metastatic breast cancers that have been previously unresponsive to one or more rounds of chemotherapy (50, 51) . Our data indicate that angiogenesis can substitute for the proliferative effects of E 2 . Therefore, counterintuitively, antiangiogenic therapies might be especially successful in ER + luminal breast cancers that exhibit intrinsic resistance to endocrine therapies.
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